Loading page
Published briefing
Full research review · published Aug 30, 9:55 AM ET
This is the briefing exactly as published on Aug 30, 2026. It is never edited afterwards, so figures and views in it are as of that date and may since have changed. It is a record, not current advice.
What Changed This Run No 8/10-or-higher idea was killed, closed, or moved across the bar, and no new 8/10 idea opened. The high-conviction book was reaffirmed rather than expanded. AVGO stayed at 8/10 because the live 3m test remains the Sept. 2 fiscal Q3 call, with Broadcom previously guiding to about $29.4B of Q3 revenue and $16.0B of AI semiconductor revenue (https://investors.broadcom.com/company-information/events-presentations; https://investors.broadcom.com/news-releases/news-release-details/broadcom-inc-announces-second-quarter-fiscal-year-2026-financial). MU stayed at 9/10 after fiscal Q3 showed 85% gross margin and DRAM/NAND price strength; the unresolved 1y question is whether fiscal Q4 and the first fiscal-2027 outlook confirm that shortage economics persist (https://www.sec.gov/Archives/edgar/data/723125/000072312526000015/mu-20260528.htm).
High-Conviction Theses Reviewed INSW stayed at 8/10: Q2 delivered record net income and adjusted EBITDA, and the board declared a $5.05 dividend payable Sept. 24 to holders of record Sept. 10, leaving Q3 realized tanker rates as the next proof point (https://www.intlseas.com/newsroom/news/news-details/2026/International-Seaways-Reports-Second-Quarter-2026-Results/default.aspx). CCJ stayed at 8/10: Cameco kept 2026 uranium production guidance at 19.5M-21.5M pounds despite operational disruptions, and Westinghouse confidentially submitted its Form S-1 on July 31 (https://www.cameco.com/media/news/cameco-reports-2026-second-quarter-results; https://www.sec.gov/Archives/edgar/data/1009001/000119312526327250/d307413dex991.htm). NOW stayed at 8/10 after Q2 subscription revenue reached $3.877B, up 23% constant currency, and ServiceNow AI crossed $1B of annual contract value (https://investor.servicenow.com/news/news-details/2026/ServiceNow-Reports-Second-Quarter-2026-Financial-Results/default.aspx).
BBIO stayed at 8/10: Q2 included $222.4M of U.S. Attruby net product revenue, while BBP-418 has a Nov. 27 PDUFA target date, Priority Review, and no advisory committee planned (https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260630xex991.htm). META stayed at 8/10: Q2 revenue rose 28% to $60.80B, ad impressions rose 14%, average price per ad rose 12%, and capex was $31.08B, keeping the thesis centered on ad growth versus AI infrastructure spend (https://investor.atmeta.com/investor-news/press-release-details/2026/Meta-Reports-Second-Quarter-2026-Results/default.aspx). RARE stayed at 8/10: Ultragenyx reaffirmed $730M-$760M 2026 revenue guidance, its 2027 profitability path, UX111’s Sept. 19 PDUFA date, and September/October timing for Phase 3 Aspire GTX-102 data; FDA also lists GENGLYCOS for GSDIa under an accelerated pathway with continued status tied to confirmatory benefit (https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-reports-second-quarter-2026-financial-results-and; https://www.fda.gov/vaccines-blood-biologics/genglycos).
TLN stayed at 8/10 after raising 2026 adjusted free cash flow guidance to $1.200B-$1.350B, while its Q2 Form 10-Q says the revised AWS PPA can provide up to 1,920 MW through 2042 and transitioned in April 2026 (https://ir.talenenergy.com/news-releases/news-release-details/talen-energy-reports-second-quarter-2026-results-raises-2026; https://www.sec.gov/Archives/edgar/data/1622536/000162253626000066/tln-20260630.htm). NXT stayed at 8/10 after Q1 FY2027 revenue of $935M, adjusted EBITDA of $233M, backlog above $5.5B, and FY2027 adjusted EBITDA guidance of $870M-$930M (https://investors.nextpower.com/news/news-details/2026/Nextpower-Reports-Q1-Fiscal-Year-2027-Financial-Results/default.aspx). MLYS stayed at 8/10 with lorundrostat’s Dec. 22 PDUFA date, $661.4M of cash and investments, and launch preparations on track, while AstraZeneca’s BAXFENDY is already the first U.S. aldosterone synthase inhibitor for inadequately controlled hypertension (https://ir.mineralystx.com/news-events/press-releases/detail/111/mineralys-therapeutics-reports-second-quarter-2026; https://www.astrazeneca-us.com/media/press-releases/2026/BAXFENDY-approved-in-the-US-as-the-first-and-only-aldosterone-synthase-inhibitor-treatment-for-adults-with-hypertension.html).
What To Watch Next Near-term 8/10+ catalysts are AVGO fiscal Q3 on Sept. 2; INSW dividend dates on Sept. 10 and Sept. 24; RARE UX111 on Sept. 19 and GTX-102 data in September or October; MU fiscal Q4 in late September; NXT Q2 FY2027 on Oct. 22; NOW and META Q3 on Oct. 28; MLYS ICER on Oct. 29; CCJ Q3 on Oct. 30; TLN Q3 and AWS/PJM updates in November; BBIO BBP-418 on Nov. 27; and MLYS lorundrostat on Dec. 22.